Lates News

According to Every AI News, Dongwu Securities released a research report on April 21 giving Xinlitai (002294.SZ) a "buy" rating. The reasons for the rating mainly include: 1) performance meets expectations, with continuous growth in revenue from innovative products; 2) smooth progress in the clinical development of JK07, with data readout window approaching; 3) innovative pipeline entering into the realization phase. (Daily Economic News)